Heterocyclic compounds and uses thereof

US8865732B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Zilin Huang · Bellevue, US
• Jeff Jin · Fremont, US
• Timothy Machajewski · Martinez, US
• William R. Antonios-McCrea · Moraga, US
• Maureen McKenna · Pinole, US
• Daniel Poon · Piedmont, US
• Paul A. Renhowe · Danville, US
• Martin Sendzik · Belmont, US
• Cynthia Shafer · El Sobrante, US
• Aaron Smith · Fremont, US
• Yongjin Xu · Castro Valley, US
• Qiong Zhang · Plano, US
• Zheng Chen · Los Angeles, US

Key dates

• Filing date: Feb 14, 2012
• Grant date: Oct 21, 2014
• Expiry date: Feb 14, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.